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ABSTRACT
URINARY MELATONIN LEVELS AND RISK OF POSTMENOPAUSAL BREAST
CANCER IN THE WOMEN’S HEALTH INITIATIVE OBSERVATIONAL STUDY

MAY 2012
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Directed by: Dr. Susan R. Sturgeon

Prior studies have observed a link between night shift work and increased risk of
breast cancer. Melatonin, a hormone related to circadian rhythm, has been proposed to
lower breast cancer risk by inhibiting cell proliferation. The disruption of peak melatonin
that occurs during night shift work could explain the increase in risk observed. Several
studies have assessed whether higher melatonin levels are associated with decreased
breast cancer risk, but results have been conflicting. We examined the relationship
between urinary melatonin levels and breast cancer risk in a nested case-control study
conducted within the Women’s Health Initiative Observational Study. First morning
urine samples collected at baseline were assayed for melatonin levels in 258 women
diagnosed with invasive breast cancer and 515 matched controls from three enrollment
sites. Using conditional logistic regression to adjust for matching factors and established
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risk factors, results indicate no association between urinary melatonin levels and breast
cancer risk. The mean creatinine adjusted melatonin levels for cases and controls were
16.30 ng/mg and 16.05 ng/mg, respectively. Compared to the lowest quartile of creatinine
adjusted melatonin, the odds of breast cancer did not vary by quartile of creatinine
adjusted melatonin, adjusted for known breast cancer risk factors: second quartile 0.84
(95% CI 0.52-1.38), third quartile 1.05 (95% CI 0.65-1.72) and fourth quartile 1.09 (95%
CI 0.66-1.81). This study does not suggest that melatonin is protective against breast
cancer and suggests that reasons other than melatonin suppression may explain the
increased risk of breast cancer seen in night shift workers.
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CHAPTER I
INTRODUCTION
The American Cancer Society has estimated that 226,870 women will be
diagnosed with breast cancer and 39,510 women will die of breast cancer in 2012 in the
United States.1 On January 1, 2008, 2,632,005 U.S women had a history of breast cancer.
From 2003 to 2007, the annual age-adjusted death rate in the United States for breast
cancer was 24 per 100,000 women per year.2 The median age of death for breast cancer
was 68 years old.2 A vast majority of breast cancers occur in postmenopausal women,
with an estimated 78.2% of breast cancer diagnoses in women over the age of 55 from
2003-2007.2
Previous literature has found a link between night shift work and breast cancer.4, 5
Interruption of melatonin production caused by night shift work may explain the increase
in breast cancer risk.5,6 Melatonin is a hormone found in the pineal gland that circulates
throughout the body and influences circadian rhythm. Melatonin may affect breast cancer
risk by decreasing cell proliferation and limiting tumor growth. Current epidemiological
literature points towards a relationship between melatonin levels and breast cancer risk. A
majority of prospective studies have found an inverse association between urinary
melatonin levels and breast cancer risk7-11, though not all results have been statistically
significant.7-9,12 Prospective studies focusing on postmenopausal women using the more
reliable first morning urine samples will aid this growing field of research. Therefore, we
conducted a nested case-control study within the Women’s Health Initiative
Observational Study to assess urinary melatonin, as measured through first morning
urine, and subsequent postmenopausal breast cancer risk.

1

CHAPTER II
REVIEW OF THE LITERATURE
Shift work and Breast Cancer Risk
In 2010, the International Agency for Research on Cancer (IARC) published a
report that concluded shift work that disrupts circadian rhythm is probably carcinogenic
to humans.5 The IARC assesses a variety of data sources, including studies conducted in
human and animals. There was limited evidence in humans for this relationship and
sufficient evidence from experiments conducted with animals. The variety of definitions
of shift work is one difficulty in assessing the relationship between cancer and shift work.
In general, shift work is defined as working irregular hours, typically outside the standard
daylight hours of 8 am to 6 pm. In the United States, shift workers make up
approximately 15% of the fulltime work force work.5
A total of eight studies have looked specifically at shift work and breast cancer
risk. A meta-analysis analyzing six of these eight studies was conducted by Megdal et al.
(2005).13 The authors found a 51% increased risk of breast cancer in these studies among
night shift workers excluding airline cabin crew, including both pre- and postmenopausal
breast cancer (RR 1.51, 95% CI 1.36-1.68). A majority of women included in these
studies were postmenopausal. Airline cabin crew were excluded from this analysis, but
when included the results were similar (RR=1.48, 95% CI 1.36-1.61). A limitation of this
meta-analysis is that each study used varying definitions of shift work, which limits the
comparability of the studies.5 Due to the fact that shift work disrupts circadian rhythm
and peak melatonin production, the hormone melatonin is often cited as a potential
biological mechanism for the association between shift work and breast cancer.

2

Biological Mechanisms of Melatonin and Breast Cancer Risk
Melatonin is a hormone that influences circadian rhythms in bacteria, plants and a
variety of vertebrates, including humans.5 As light enter the eyes, the information is
processed by the hypothalamus sending a signal to the pineal gland, which secretes
melatonin. The peak melatonin secretion occurs during the night, between 2-3 am, but
can be suppressed by light.5,6 In experimental studies, it has been found that animals that
are either exposed to light during typical dark periods or who have received a
pinealectomy, the removal of the pineal gland, can experience disruption in the timing
and the duration of melatonin secretion.5 A growing body of literature suggests that night
shift work is related to breast cancer risk through nighttime light exposure, and perhaps
lower melatonin levels. There has been some conflicting evidence in this regard, as a
recent study conducted within Canadian nurses by Grundy et al. (2011) has found no
association between night shift light exposure and melatonin levels.14 No significant
decrease in melatonin levels was found between female nurses working the night shift
and those working the day shift on a rapidly rotating shift schedule. The authors did
address the fact that light exposure experienced by the nurses within the study, 37.2 lux,
was well below the level found to decrease melatonin levels in experimental studies, 200
lux. The effects of melatonin on breast cancer are only recently beginning to be
understood, but it is hypothesized that melatonin is able to effect breast cancer risk
through suppression of cell growth and proliferation.5,6
Studies have shown that melatonin is able to suppress the proliferation of both
estrogen receptor alpha-positive and estrogen receptor negative human breast cancer cells
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in vitro.6 A linear dose response relationship has been observed between melatonin and
suppression of these cells, indicating that higher levels of melatonin is associated with
increased cancer cell suppression.6 Melatonin is able to block estrogen receptors, thus
decreasing the likelihood that the breast cancer will be able to form.
The anti-proliferative effect of melatonin is believed to occur through at least four
pathways.5 First, the prevention of the uptake of linoleic acid has been shown to have an
inhibitory effect, preventing the growth of tumor cells.5,15 Linoleic acid is thought to be
an energy source for tumor growth, so inhibition of linoleic acid by melatonin would
prevent excess cell growth.15 Second, in experimental studies done in vitro, melatonin has
been shown to inhibit the mitogenic action of hormones and growth factors, e.g. estradiol
and prolactin. This again prevents the growth of cancerous cells. Third, melatonin
increases the expression of the tumor suppressor gene TP53. Finally, melatonin down
regulates aromatase expression. This down regulation diminishes the rate of tumor
growth and proliferation.5
Overall, melatonin has been found to suppress cell proliferation. This inhibition of
cell proliferation, through the blockage of estrogen and linoleic acid receptors, inhibition
of growth factors and hormones, increase of TP53 and down regulation of aromatase, is
the mechanism through which higher levels of melatonin might protect women against
breast cancer.5,6,15
Epidemiology of Melatonin and Breast Cancer Risk
Relatively few studies have examined the relationship between urinary melatonin
levels and breast cancer risk.7-12 Five prior studies were nested case-control studies in
which the cases and controls came from large prospective cohort studies 8-12 and one was
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a retrospective case-control study.7 The following are the three studies which included
information on postmenopausal breast cancer.9,10,12
In the first prospective study to consider the association of urinary melatonin
levels and breast cancer risk, Travis et al. conducted a matched nested case-control study
of 127 cases and 353 controls participating in the Guernsey Cohort, a prospective cohort
study of 5,093 women living on the island of Guernsey in the British Isles from 1977 to
1985.12 This is the only study to use the 24-hour method of urine collection. Women
answered a baseline questionnaire that included information on reproductive history,
menopausal status, past use of oral contraceptives and other hormones and breast cancer
screening history. After recruitment, women were asked to provide a 24-hour urine
sample. Breast cancer cases were obtained through the Wessex Cancer Registry, death
certificates, and pathology reports through October 31, 2001. Each case was matched to
three controls on the basis of age, date of recruitment and menopausal status.
Urine samples were thawed and assayed by radioimmunoassay with 125I-labeled
tracer in 2002. Among postmenopausal women only, relative to the women in the first
tertile, those in the second tertile of creatinine adjusted melatonin had 24% lower risk of
breast cancer (OR = 0.76, 95% CI 0.31-1.84) and women in the third tertile of melatonin
had 1.09 times the risk of breast cancer compared to those in the lowest tertile of
creatinine adjusted melatonin (OR=1.09, 95% CI 0.46-2.6). When restricted to only
women with invasive breast cancer, the results did not change significantly. Although
there was a wide confidence interval, this study suggests there is no association between
melatonin and breast cancer risk. This study, however, may be subject to nondifferential
misclassification of the exposure, as the 24-hour sample method has not been found to be
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reliable for measuring peak melatonin levels that occur during the night.4,7 The study also
had a small sample size, limiting its power to find a modest association between
creatinine adjusted melatonin levels and breast cancer risk.
In the largest study to date, using first morning urine collection, Schernhammer et
al. conducted a nested case-control study of 357 cases and 533 matched controls to
evaluate the relationship between creatinine adjusted urinary melatonin and breast cancer
risk in the Nurses’ Health Study, a prospective cohort that began in 1976, following
121,700 registered nurses ages 30 to 55 in the United States.10 At baseline, eligible nurses
completed a questionnaire about their health status, medical history and known or
suspected risk factors for cancer and heart disease. These questionnaires were
administered every two years to identify new risk factors and diagnosis of disease. In
December 2002, 18,706 women provided a blood sample as well as a first morning urine
sample. Time of menstrual cycle was not recorded, as most of the cohort was
postmenopausal at the time of collection. Cases were defined as women who were not
diagnosed with any cancer, except for non-melanoma skin cancer, prior to urine
collection and were diagnosed with breast cancer during follow-up through May 31,
2006. Two controls were matched for each case on year of birth, menopausal status,
recent postmenopausal hormone use, month and time of day of urine collection and
fasting status at urine draw. The exceptions were postmenopausal breast cancer cases
with hormone use who were matched with only 1 control.
Relative to women in the lowest quartile of creatinine adjusted melatonin, women
in the second quartile had 1.17 times the risk of invasive breast cancer (OR 1.17, 95% CI
0.75-1.82), women in the third quartile had a 30% lower risk of invasive breast cancer
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(OR=0.70, 95% CI 0.43-1.12) and women in the fourth quartile of melatonin had a 26%
lower risk of invasive breast cancer (OR=0.74, 95% CI 0.46-1.21), (ptrend = 0.03). The
associations seen between in situ breast cancer and creatinine adjusted melatonin, though
based on small numbers, were stronger than those seen for invasive breast cancer, with
women in the highest quartile at 77% lower risk of in-situ breast cancer compared to
those in the lowest quartile (OR=0.23, 95% CI 0.08-0.69). There were no significant
differences in the results when restricted to women with ER+ receptor status. One
limitation of the study is the relatively short follow-up time. Urine collection occurred in
2002 and all cases were diagnosed by 2006, with an average follow-up time of 2.5 years
for the cases. Restricting analysis to those women who were diagnosed after 2 years did
not significantly alter the results. The short follow-up time could mean that melatonin
levels were already being affected by undiagnosed breast cancer.
The first nested case-control study to look at only postmenopausal breast cancer
was conducted by Schernhammer at al. among 178 cases and 710 controls within the
ORDET cohort, an Italian study that recruited women from 1987 through 1992.9 At
baseline, women completed a questionnaire of health characteristics, as well as provided
a blood and urine sample. Each case was matched with 4 controls that were free of cancer
at the time of the diagnosis for the case, matching on age at enrollment, date of
recruitment and laboratory batch. Urine collection was completed through a twelve-hour
overnight collection. Relative to women in the first quartile of melatonin levels, women
in the second quartile of melatonin levels had a 30% lower risk of invasive breast cancer
(OR=0.70, 85% CI 0.43-1.14), women in the third quartile of melatonin levels had 18%
lower risk of invasive breast cancer (OR=0.82, 95% CI 0.50-1.34) and women in the
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fourth quartile of melatonin levels had a 41% lower risk for invasive breast cancer
(OR=0.59. 95% CI 0.35-1.00), (ptrend = 0.04). This study did not include any information
on sleep disturbance or night shift work, which could have been an important factor to
include in the analysis. A subanalysis was conducted using creatinine adjusted melatonin
levels, which did not significantly change the results. Inclusion of the 7 cases of in situ
breast cancer also did not change the results. Removal of current smokers strengthened
the results, while restriction to current smokers caused an increase in risk when
comparing the highest tertile of melatonin to the lowest (OR=3.55, 95% CI 0.61-20.8).
The results were limited due to small number of current smokers. Exclusion of those
diagnosed within 2 years and 4 years of urine collection strengthened the results (highest
versus lowest quartile of melatonin OR=0.35, 95% CI 0.17-0.71, OR=0.34, 95% CI 0.150.75, respectively).
Overall, the literature is conflicting on the association between urinary melatonin
levels and breast cancer risk. Conflicting results may be due to poor assessment of
urinary melatonin, such as through 24-hour samples as opposed to the more reliable first
morning sample. Nested case-control studies that used the overnight and first morning
urinary analysis9-11 found a non-significant inverse relationship between urinary
melatonin and breast cancer risk, while those studies using 24-hour samples found no
association between creatinine adjusted melatonin and breast cancer risk.8 Additionally,
retrospective case-control studies are unable to assess urinary melatonin until after the
diagnosis of breast cancer, which could have altered melatonin level and may explain the
lack of significant results in this study design.7 One study has limited follow-up and
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could potentially be finding the effect of undiagnosed breast cancer altering melatonin
levels.10
Summary
The Surveillance Epidemiology and End Results (SEER) program of the National
Cancer Institute estimates that 1 out of 8 woman born today will be diagnosed with breast
cancer in their lifetime.2 With increased amount of light exposure and sleep disruption,
through night shift work or otherwise, there is a possibility that melatonin levels could be
suppressed and potentially lead to an increased risk of breast cancer via less inhibition of
breast cancer cells and their receptors.6 Current studies lack lengthy follow-up periods
and adequate collection of urine samples from women prior to their diagnosis of breast
cancer. More prospective research needs to be conducted in order to assess the
relationship between melatonin and breast cancer.
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CHAPTER III
METHODS
Study Aims and Hypothesis
Specific Aim: We evaluated the association between urinary levels of melatonin
and risk of postmenopausal invasive breast cancer through a nested case-control study
among participants from the Women’s Health Initiative Observational Study.
Hypothesis: There is an inverse association between urinary melatonin levels and
risk of postmenopausal invasive breast cancer.
Study Design and Population
To examine the association between urinary melatonin levels and risk of breast
cancer, we conducted a nested case-control study within the Observational Study (OS)
arm of the Women’s Health Initiative (WHI) among total of 258 cases of invasive
postmenopausal breast cancer and 515 matched control subjects.
The OS recruited women from September 1993 to December 1998, enrolling a
total of 93,676 women who were followed for eight to twelve years. Eligible women
were between the ages of 50-79 years old, postmenopausal at enrollment (no menstrual
cycles for at least twelve months prior to enrollment if 54 years old or younger and six
months if 55 years old or older) with the intention to reside in the area for at least 3 years
after enrollment. Exclusion criteria included any medical condition that had a predicted
survival rate of less than 3 years, as well as any conditions that may have limited the
ability to comply or stay within the study, such as alcohol or drug dependency, mental
illness, dementia or active participation in another randomized control trial.3 Both cases
and controls also had the following exclusion criteria: self-reported history of any cancer
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prior to WHI enrollment (other than non-melanoma skin cancer), self-report and/or
adjudicated cancer during WHI follow-up (other than non-melanoma skin cancer or
breast cancer for cases) and inadequate urine from screening visit 1.
Exposure Assessment
The exposure of interest is first morning urinary melatonin. Women who enrolled
in the OS provided a first morning urine sample at one of three bone density sites
(Birmingham, Pittsburgh and Tucson) at screening visit 1. When the liver metabolizes
melatonin, it becomes the metabolite 6-sulfatoxymelatonin (aMT6s) found in the urine.
Urinary melatonin level, aMT6s, was assessed through competitive enzyme-linked
immunosorbent immunoassay (ELISA) and adjusted for creatinine levels to control for
urine volume. The aMT6s levels were assessed as both a continuous and ordinal variable,
divided into quartiles based upon levels within the controls.
Validity of Exposure Assessment
ELISA has been shown to be reliable for measuring aMT6s levels, with intraassay and interassay correlation coefficients of 7.1 and 11.9% respectively, meaning that
there is little variation between and within samples, thus small chances for laboratory
errors.16 Baskett et al. found that urinary melatonin levels were correlated with plasma
melatonin levels in elderly populations (R2 = 0.797).17 Urinary melatonin can be used to
measure peak melatonin levels, as opposed to having to use a more invasive nighttime
blood draw.17 Additionally, this metabolite has been found to be highly correlated with
peak overnight melatonin levels when measured as a first morning urine void.18,19 Data
from the Nurses’ Health Study also found an intra-class correlation coefficient of 0.72 for
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first morning urine void over a three-year period, indicating that melatonin levels are
relatively stable over time.4
Outcome Assessment
Cases and controls were individually matched on enrollment date, age at
enrollment and randomization clinic, with a ratio of 1:2 cases to controls. Cases are
women who had adjudicated diagnosis of invasive breast cancer at one of three
enrollment sites during their WHI follow-up (Birmingham, Pittsburgh and Tucson).
Cases reported their breast cancer diagnosis through the annual questionnaire. Those who
reported a breast cancer diagnosis had their medical records reviewed to adjudicate the
diagnosis.20 Controls were women from these enrollment sites without a breast cancer
diagnosis (invasive or non-invasive) during their WHI follow-up.
Validity of Outcome Assessment
The baseline questionnaire for enrollment into the WHI has very high reliability,
with a reliability coefficient of 0.89 for reporting of a history of breast cancer.13
Additionally, self-report of breast cancer has been found to be a reliable measure of
breast cancer rates in observational studies.22-24
Covariate Assessment
Data on demographics, physical characteristics, behavioral characteristics,
medication use and additional variables believed to be associated with breast cancer were
collected through standardized questionnaires administered at baseline and updated over
the course of followup.21 The variables of interest for this study include age, ethnicity,
education level, height, weight, body mass index, hormone use, history of breast biopsy
and benign breast disease, age at menarche, age at menopause, type of menopause
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(natural, hysterectomy, bilateral oophorectomy), age at first child’s birth, number of
pregnancies, breast feeding, marital status, prior needle aspiration of a breast lump, oral
contraceptive use, current medication, first degree relative with breast cancer, energy
expenditure from physical activity (MET hr/wk), sleep quality, alcohol intake and
smoking status.
Statistical Analysis
Upon inspection of the data, it was found that one case had missing melatonin
levels and one control had a melatonin level that was an obvious outlier (1971.28 ng/mg).
These participants were removed from analysis, along with their matched pairs. This left
773 observations for analysis, 258 cases and 515 matched controls. We used t-tests and
chi square tests as appropriate to test if there was a difference in the covariates of interest
in cases and controls. A t-test was also conducted to see if there was a difference between
mean melatonin levels in cases and controls (Table 1). Those categorical variables with
small cell counts were collapsed. The distribution of continuous melatonin levels,
adjusted for creatinine, was assessed for normality using the Shapiro-Wilk test. Due to
the non-normal distribution of melatonin, Kruskal-Wallis tests were used to test whether
the median creatinine adjusted melatonin levels in controls differed by covariates (Table
2).
As this was a matched study design, we used conditional logistic regression to
determine if higher levels of creatinine adjusted urinary melatonin is associated with
lower odds of invasive breast cancer. We divided creatinine adjusted melatonin levels
into quartiles based on control levels, using the lowest level of melatonin as the referent
group.
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To address potential confounding, we included covariates identified in previous
studies as known risk factors for breast cancer established within WHI25, as well as
covariates included in other studies assessing the relationship between melatonin and
breast cancer risk. Due to small numbers, ethnicities collapsed into white, black or other
race. Highest education levels were collapsed into high school or less, college, post
graduate or missing. Marital status was collapsed into never married, divorced/separated,
widowed, married or marriage like relationship, or missing. Age at menarche was
collapsed into 11 or less, 12-13 years, 14-15, 16 or older or missing. Hours of sleep was
collapsed into 5 or less hours, 6 hours, 7 hours, 8 hours, 9 or more hours, or missing.
Estrogen and progesterone duration was collapsed into none, less than 5 years, 5 to less
than 10 years, 10+ years or missing. Body mass index was collapsed into less than or
equal to 24.9, 25-29.9, 30-34.9, or 35+. Quality of sleep was collapsed into restless,
average quality, or restful. Hysterectomy, needle aspiration, bilateral oophorectomy were
included as ever/never. Oral contraceptive use and female relative with breast cancer
were included as yes/ no. Smoking status was included as never, past or current smoker.
Number of live births was included as never pregnant, never had term pregnancy, 1, 2-4,
or 5+ pregnancies. Age at first birth was included as never pregnant, less than 20 years,
20-29 years, 30+ years or missing. Alcohol intake, total energy expenditure and age of
menopause were continuous variables. Age and region were controlled for by their use as
matching factors.
Regression analyses began with the fitting of single predictor conditional
regression models for each variable with the outcome of invasive breast cancer (Table 1).
These results were used to assess the predictive significance of WHI breast cancer risk
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factors and established risk factors used in other studies. An initial multiple predictor
conditional logistic regression model was fit controlling for matching factors (enrollment
date, age at enrollment and enrollment site) with the following predictors: ethnicity, age
of menopause, needle aspiration of the breast, energy expenditure from recreational
activities, duration of estrogen and progesterone use, time since quitting hormone
replacement therapy, body mass index and highest education level. Adjusted odds ratios
were calculated using the lowest creatinine adjusted melatonin quartile as the referent
group (Table 3). Predictors in this initial multiple predictor conditional logistic regression
model was retained for inclusion in subsequent models if its associated likelihood ratio
test was statistically significant at p <0.10. Another multiple predictor conditional logistic
regression model was fit using creatinine adjusted melatonin as a continuous variable.
We conducted sensitivity analysis by removing current smokers from our analysis
as a previous study had found an effect by smoking status.9 We also estimated a model in
which we restricted our analysis to only those with ER+ receptor status to see if there was
any difference in this population as previous studies had looked at this population (Table
4). 9,10
To assess the potential for a disease effect of undiagnosed breast cancer, another
model was fit restricting the population into those diagnosed before and after 4 years
from urine collection. Then, we divided the population into those diagnosed from 4-7
years and those diagnosed after 7 years (Table 5).
Finally, while previous studies have not found a significant relationship between
sleep duration and melatonin levels10, we constructed a model with sleep duration and
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breast cancer risk, to see if there was any association (Table 6). All statistical analysis
was conducted using Stata V. 12.1.
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CHAPTER IV
RESULTS
Mean creatinine adjusted melatonin levels were 16.29 ng/mg (sd=11.9) for cases
and 16.05 ng/mg (sd=12.9) for controls. Characteristics of cases and controls are shown
in Table 1 along with crude odds ratios from single predictor conditional logistic
regression. At baseline, cases and controls differed in a few characteristics.
Contrary to what is typically seen in breast cancer studies, women who had a later
age at first birth were at a lower risk of breast cancer relative to women who had their
birth at less than 20 years of age. The risk of breast cancer was 26% lower for women
who gave birth at 20-29 years old (95% CI 0.47-1.18), 42% lower for women who gave
birth at 30 or older (0.28-1.21) and there was no association for women who never gave
birth (OR=0.99, 95% CI 0.56-1.75) relative to women who had their first birth at less
than 20 years old. All other known breast cancer risk factors indicated the correct
direction of risk for breast cancer. With each one-point increase in body mass index there
was a 1.12 times increased risk of breast cancer (95% CI 0.96-1.30). For each one-year
increase in age of menopause, there was 1.02 times increased risk of breast cancer (0.991.04). Relative to women who never used estrogen and progesterone, women who used
for 5-10 years had 1.75 times the risk of breast cancer (95% CI 1.01-3.01) and women
who used for 10 or more years had 1.05 times the risk of breast cancer (0.54-2.05).
Women who received a needle aspiration of the breast had 1.30 times the risk of breast
cancer relative to women who had never received a needle aspiration (95% CI 0.87-1.95).
Women who had a bilateral oophorectomy or a hysterectomy had a 46% (95% CI -.340.85) and 33% (95% CI 0.50-0.94) reduction in breast cancer risk, respectively. Women
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with a family history of breast cancer had 1.85 times the risk of breast cancer relative to
women with no family history (95% CI 1.67-2.92). Women who were past or current
smokers had 1.08 (95% CI 0.80-1.46) and 1.32 (95% CI 0.72-2.40) times the risk of
breast cancer relative to women who never smoked. Quality of sleep and hours of sleep
were not significantly associated with breast cancer risk. Compared to those who only
completed high school, those who completed a graduate education had 2.2 times the risk
of breast cancer (95% CI 1.47-3.28).
Median levels of creatinine adjusted melatonin by breast cancer risk factors are
presented in Table 2. Creatinine adjusted melatonin levels decreased as body mass index
increased. Those who completed higher levels of education had higher levels of
creatinine adjusted melatonin. There was a general decrease in creatinine adjusted
melatonin as age increased. Women who had given birth to more children had higher
levels of creatinine adjusted melatonin, as compared to women who had not given birth.
Higher levels of quality of sleep and duration of sleep both led to higher levels of
creatinine adjusted melatonin, though levels were fairly similar for those who slept 7, 8 or
9 hours. Never smokers appear to have lower levels of creatinine adjusted melatonin
compared to past and current smokers, who have similar levels.
The initial multiple predictor conditional logistic regression model of breast
cancer and creatinine adjusted melatonin (coded as quartiles) included matching factors
plus the following confounders: age of menopause, needle aspiration of the breast,
duration of estrogen and progesterone therapy, years since quitting hormone replacement
therapy, body mass index, ethnicity, energy expenditure from physical activity and
highest education level. Each covariate was taken out of the model one at a time and a
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likelihood ratio test was conducted to see if the covariate was statistically significant.
Any covariate with a p-value less than 0.05 were included in the final model. Age of
menopause, needle aspiration, duration of estrogen and progesterone therapy, years since
quitting hormone replacement therapy, ethnicity and energy expenditure from physical
activity had p-values greater than 0.05, and were dropped from the model, leaving highest
education level and body mass index. The odds ratio and 95% CI for the model adjusted
for body mass index and education level are presented in Table 3 as the multivariable
model. In the fully adjusted model, relative to the lowest quartile of creatinine adjusted
melatonin, the risk of breast cancer was 0.85 (95% CI 0.52-1.37), 1.05 (95% CI 0.651.72), and 1.09 (95% CI 0.66-1.81) for women in the second, third and fourth quartile,
respectively. In the model adjusted for body mass index and education level, relative to
the lowest quartile of creatinine adjusted melatonin, the risk of breast cancer was 0.98
(95% CI 0.63-1.54), 1.26 (95% CI 0.80-1.97), and 1.20 (95% CI 0.76-1.90) for women in
the second, third and fourth quartile, respectively. When analysis was run with creatinine
adjusted melatonin as a continuous variable the results did not change (OR=1.00, 95% CI
0.99-1.01). After adjusting the continuous creatinine adjusted melatonin for known breast
cancer risk factors the results did not change (OR=1.01, 95% CI 0.99-1.02).
In ancillary analysis, we explored whether there was an association between sleep
duration and breast cancer risk (Table 4). From the fully adjusted model, adjusting for
age of menopause, needle aspiration, duration of estrogen and progesterone therapy,
years since quitting hormone replacement therapy, ethnicity and energy expenditure from
physical activity, we found that compared to women who slept 5 hours or less, the risk of
breast cancer was 0.87 (95% CI 0.43-1.75), 1.05 (95 % CI 0.53-2.11), 0.92 (95% CI 0.43-
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1.97) and 0.71 (95% CI 0.26-1.92) for those who slept 6 hours, 7 hours, 8 hours and 9+
hours, respectively. The results did not significantly change was adjusting for creatinine
adjusted melatonin.
We assessed differences in results by tumor receptor status and smoking status.
The odds ratios for the analysis restricted to those who were ER+ and stratified on
smoking status are presented in Table 5. Among the women with ER+ receptor status
(n=176), relative to the lowest quartile, the risk of breast cancer was 0.69 (95% CI 0.391.23), 0.72 (95% CI 0.40-1.29) and 0.83 (95% CI 0.46-1.51) for the women in the
second, third and fourth quartile, respectively. There were too few women who had ERreceptor status to complete an analysis (n=36). The remaining women had borderline
(n=1), unavailable (n=9) or unknown receptor status (n=17).
When current smokers were excluded, the risk of breast cancer relative to women
in the lowest quartile of creatinine adjusted melatonin is 1.01 (95% CI 0.60-1.70), 1.19
(95% CI 0.70-2.02) and 1.41 (95% CI 0.81-2.44) for women in the second, third and
fourth quartile respectively. There were too few current smokers to analyze the
association of melatonin and breast cancer in this subgroup (20 cases and 31 controls).
In another ancillary analysis, we considered the subgroup of women diagnosed
within 4 years of urine collection, women diagnosed between 4 to 7 years after urine
collection and those diagnosed 7 or more years after urine collection. The results of these
analyses are presented in Table 6. In every subgroup we found no association between
creatinine adjusted melatonin and breast cancer risk. For those diagnosed within 4 years,
relative to women in the first quartile of creatinine adjusted melatonin, the odds ratios are
0.86 (95% CI 0.32-2.30), 1.42 (95% CI 0.54-3.75) and 1.40 (95% CI 0.51-3.81) for
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women in the second, third and fourth quartile respectively. For those diagnosed between
4-7 years after diagnosis, relative to women in the first quartile of creatinine adjusted
melatonin, the odds ratios are 0.52 (95% CI 0.18-1.52), 1.79 (95% CI 0.67-4.76) and 1.26
(95% CI 0.49-3.12) for women in the second, third and fourth quartile respectively. For
those women diagnosed 7 or more years are urine collection, relative to women in the
first quartile of creatinine adjusted melatonin, the odds ratios are 0.85 (95% CI 0.851.94), 0.81 (95% CI 0.33-1.95) and 0.94 (95% CI 0.42-2.13) for women in the second,
third and fourth quartile respectively.
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CHAPTER V
DISCUSSION
Contrary to our hypothesis, this study did not find a statistically significant
relationship between urinary melatonin and breast cancer risk. The aim of this study was
to examine the relationship between creatinine adjusted urinary melatonin levels and
invasive breast cancer risk in postmenopausal women. The Women’s Health Initiative
Observational Study presented an opportunity to use a large prospective cohort with a
long follow-up and first morning urine sample. Several studies have looked at urinary
melatonin and breast cancer risk, but results have been conflicting.7-12
The mean creatinine adjusted melatonin found in our study, 16.29 ng/mg for cases
and 16.05 ng/mg for controls, was different than what has been seen in previous studies.
The means found within our study were higher compared to Travis et al., who found
means of 6.47 ng/mg for cases and 6.57 ng/mg for controls.12 The tertile cutoff points
were also lower than our quartile cutoff points. The study conducted within the Nurses
Health II also found lower mean creatinine adjusted melatonin levels, 10.8 ng/mg for
cases and 12.7 ng/mg for controls.11 The quartile cutoff points used were similar, but
slightly higher for this study. The final three prospective studies conducted to date had
higher mean creatinine adjusted melatonin levels, 29.3 ng/mg for cases and 27.6 ng/mg
for controls8, 21.0 ng/mg for cases and 23.5 ng/mg for controls9, 24.5 ng/ng for cases and
28.8 ng/mg for controls.10 Two of these studies did not use creatinine adjusted melatonin
to create the quartiles8,9. The one study that did use creatinine adjusted melatonin
quartiles had higher quartile cutoff points than our study.10

22

Of the five prospective studies conducted to date, one examined premenopausal
women8, two examined both pre- and postmenopausal women11,12 and two examined only
postmenopausal women.9,10 A nested case-control conducted within the Nurses Health
Study II among mostly premenopausal women found an inverse association between
melatonin and breast cancer risk, the risk for invasive breast cancer for the highest
quartile of creatinine adjusted melatonin compared to the lowest was 0.59 (95% CI 0.341.00).11 This association was slightly weakened when those women with in situ breast
cancer were included (OR=0.68, 95% CI 0.44-1.06). In comparison, the study conducted
in the ORDET cohort among premenopausal women found a risk of 1.43 (95% CI 0.832.45) for all breast cancers comparing the fourth quartile of melatonin to the first.8 A
statistically significant inverse association was found in only one subgroup analysis, that
of women who were diagnosed 8 years after urine collection. In the study conducted
within the Guernsey cohort, no association was found between urinary melatonin levels
and breast cancer risk in either pre or postmenopausal women.12 The authors used a 24hour collection of urine, which would not accurately measure the peak melatonin
production, which was stated as a possible reason for the lack of association.9,10,12 We
used a first morning sample and were able to capture the peak melatonin level, so this is
not a limitation for our study. The study conducted within the Nurses Health Study found
an inverse association between creatinine adjusted melatonin and breast cancer risk
(OR=0.62, 95% CI 0.41-0.95 for the fourth quartile compared to the first).10 This
association was weakened when in situ cancers were removed (OR=0.74, 95% CI 0.461.21 for the fourth quartile compared to the first), as compared to the Nurses Health II,
which found less of an association with in situ breast cancer among premenopausal
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women.8 The ORDET cohort investigators found an inverse relationship between
melatonin and breast cancer risk (OR=0.65, 95% CI 0.39-1.09 for the fourth quartile
relative to the first quartile).9 The association increased when current smokers were
excluded from the analysis (OR=0.38, 95% CI 0.20-0.74).
The cases in our study were all diagnosed with invasive breast cancer, so we were
unable to assess variations in the association between in situ and invasive breast cancer as
seen in previous studies.10-12 When we excluded current smokers the risk of breast cancer
appears to have increased, but this was non-significant. Previous studies that restricted to
ER+ receptor status saw no change in risk.9,10 We saw an inverse relationship between
creatinine adjusted melatonin and breast cancer risk when we restricted to ER+ receptor
status, but this was non-significant. Unlike the study that found a significant inverse
association when analysis was restricted to women diagnosed 8 years after urine
collection8, we found no difference when we limited the analysis to those women who
were diagnosed 7 years after urine collection.
One possible limitation of our study is nondifferential misclassification of
exposure. The first morning urine samples were assayed for melatonin levels using the
ELISA method, a validated method.6 If melatonin levels were incorrectly measured, this
misclassification would attenuate the results seen in this study. This is unlikely to occur,
as the ELISA assay is a validated assay. Additionally, the lab personnel were blinded to
the case status of the urine samples. It is possible that the urine samples were incorrectly
collected or stored. This would also attenuate the results seen. Urinary melatonin levels
have been found to be stable over time, allowing for one sample to be a representative
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sample over many years, so the sample collected at baseline should be an accurate
representation of melatonin exposure over time.8
Within the context of a nested case-control study, selection bias will occur if
participants differentially drop out of the study based upon exposure and disease status. If
a differential loss to follow-up occurred this could cause either an increase or decrease of
the association seen. This is unlikely in our study, as all the women were followed very
closely for many years and any women who did not complete a questionnaire was crossreferenced against breast cancer registries and the National Death Index to see if they had
died or gone on to develop a disease. Additionally, the completion rates of the annual
questionnaires were between 93-96%, indicating that there was a high degree of followup.20
The Women’s Health Initiative is a large prospective cohort, which allowed for
the collection of many potential confounding factors. Using information gathered from
the baseline questionnaire, as well as the subsequent questionnaires, we were able to
evaluate and control for many potential confounding factors. We assessed known breast
cancer risk factors as identified from other WHI studies, as well as other factors
considered in independent studies assessing urinary melatonin and breast cancer risk.
While we were able to address many known confounders, it is possible that we have
missed other lesser-known factors.
The results of this study is plausibly generalizable to all women at risk for
postmenopausal breast cancer, as there is no reason to believe that the biological
mechanism through which melatonin affects breast cancer risk varies. It is possible that
menopausal status could alter the relationship between melatonin and breast cancer, as
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pre- and postmenopausal breast cancers have different physiological mechanisms. Thus,
more research will have to be conducted to see if the relationship between melatonin
levels and pre- and postmenopausal breast cancer risk differ.
In summary, our study found no association between creatinine adjusted
melatonin levels and invasive postmenopausal breast cancer risk. Relatively few studies
have assessed the relationship between melatonin and risk of postmenopausal breast
cancer and have provided inconsistent results.7-12 Using a sample from the large Women’s
Health Initiative Observational Study cohort allowed for a large number of women to be
assessed for a long period of follow-up. Additionally, the urine sample was collected as a
first morning urine sample, believed to be a more reliable estimate than the 24-hour
sample method. Analysis accounting for lag time, smoking status and ER+ receptor status
did not significantly alter our findings. Additional studies will be needed that allow for
long periods of follow-up, a large study population and first morning urine samples to
confirm our results.
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APPENDIX A
HUMAN SUBJECT PROTECTION
All subjects recruited to the Women’s Health Initiative signed an informed
consent agreement understanding that they would participate in a longitudinal cohort
study. Consenters also understood that they could discontinue their participation at any
time. To protect confidentiality, all identifying factors were removed from the data set
prior to our receipt. In our dataset, all participants are only identified by a study ID.
There were no known risks to participation in this study. The only potential
concern is privacy and confidentiality, but we analyzed de-identified data and it was
stored on a secure file. There were no known benefits for the study participants, other
than contributing pertinent scientific data for this and other studies.
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APPENDIX B
PERMISSION TO ACCESS DATA
I received permission to use Women’s Health Initiative Observational Study data
to assess the relationship between melatonin levels and risk of postmenopausal breast
cancer.
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APPENDIX C
TABLES
Table 1. Baseline characteristics of postmenopausal breast cancer cases and matched controls (N=773)
Cases (n=258)
16.29 ng/mg
(11.9)

Controls (n=515)
16.05 ng/mg
(12.9)

p-valuea
0.801

OR

95% CI

Age stratum at
enrollment n (%)
50-54
55-59
60-69
70-79

32 (12.40%)
48 (18.60%)
119 (46.12%)
59 (22.87%)

70 (13.59%)
89 (17.28%)
250 (48.54%)
106 (20.58%)

0.805

1.0 (referent)
2.0
1.84
4.4

0.59-6.74
0.39-8.78
0.68-28.23

Ethnicity n (%)
White
Black
Other race

211 (81.78%)
31 (12.02%)
16 (6.2%)

418 (81.17%)
60 (11.65%)
37 (7.18%)

0.874

1.0 (referent)
1.02
0.77

0.61-1.72
0.35-1.70

Highest education level
n (%)
High school or less
College
Post graduate

88 (34.11%)
81 (31.40%)
86 (33.33%)

220 (43.72%)
182 (35.34%)
108 (20.97%)

0.001

1.0 (referent)
1.13
2.20

0.78-1.64
1.47-3.28

0.068

1.0 (referent)
5.7

1.10-29.58

0.72
0.83
1.14

0.38-1.39
0.52-1.33
0.65-2.01

1.12

0.96-1.30

Covariate
Creatinine adjusted
melatonin level mean
(sd)

Number of live births n
(%)
Never pregnant
Never had term
pregnancy
1
2-4
5+

31 (12.02%)
7 (2.71%)

54 (10.49%)
3 (0.58%)

23 (8.91%)
148 (57.36%)
47 (18.22%)

56 (10.87%)
321 (62.33%)
78 (15.15%)

BMI categories n (%)
<24.9
25-29.9
30-34.9
35+

90 (34.88%)
85 (32.95%)
45 (17.44%)
36 (13.95%)

203 (39.42%)
171 (33.20%)
81 (15.73%)
56 (10.87%)

0.455

Quality of sleep n (%)
Restless
36 (13.95%)
65 (12.62%)
0.211
1.0 (referent)
Average quality
121 (46.90%)
212 (41.17%)
1.04
0.65-1.68
Restful
100 (38.76%)
232 (45.05%)
0.78
0.49-1.25
Notes: a. P-value for t-tests or chi-squared tests, as appropriate
Abbreviations: OR- Odds Ratio, sd- Standard Deviation, se- standard error, BMI- Body Mass Index, HRTHormone replacement therapy
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Table 2. Median creatinine adjusted melatonin levels by baseline characteristics in 515 controls
a
Covariates
Median Creatinine Adjusted Melatonin (ng/mg) P-value
Age stratum at enrollment
50-54 (n=70)
11.00
0.03
55-59 (n=89)
17.60
60-69 (n=250)
13.24
70-79 (n=106)
10.79
Ethnicity
White (n=418)
Black (n=60)
Other (n=37)

14.42
9.48
10.45

0.05

Highest education level
High school or less (n=220)
College (n=182)
Post graduate (n=108)
Missing (n=5)

11.60
14.52
14.81

0.06

Number of live births
Never pregnant (n=54)
Never had term pregnancy (n=3)
1 (n=56)
2-4 (n=321)
5+ (n=78)
Missing (n=3)

13.24
6.69
10.75
13.90
15.39

0.38

BMI categories
<24.9 (n=203)
25-29.9 (n=171)
30-34.9 (n=81)
35+ (n=56)
Missing (n=4)

14.57
14.07
12.09
9.70

0.0068

Quality of sleep
Restless (n=65)
Average quality (n=212)
Restful (n=232)
Missing (n=6)

11.30
12.42
14.64

0.33

Hours of sleep
5 or less hours (n=36)
6 hours (n=134)
7 hours (n=209)
8 hours (n=104)
9 or more hours (n=28)
Missing (n=4)

10.20
11.23
14.40
15.47
14.92

0.48

Notes: a. P-value from Kruskal-Wallis test
Abbreviations: OR- Odds Ratio, BMI- Body Mass Index, HRT-Hormone replacement therapy
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Table 3. Odds ratios (OR) and 95% confidence intervals of breast cancer by quartile
of creatinine adjusted melatonin
Number
Unadjusted OR Fully Adjusteda OR Multivariableb OR
of cases
(95% CI)
(95% CI)
(95% CI)
/controls
1.00 (Referent)
1.00 (Referent)
1.00 (Referent)
Quartile 1 58/127
1.02 (0.66-1.56)
0.85 (0.52-1.37)
0.98 (0.63-1.54)
Quartile 2 60/130
1.26 (0.82-1.94)
1.05 (0.65-1.72)
1.26 (0.80-1.97)
Quartile 3 60/130
1.13 (0.73-1.75)
1.09 (0.66-1.81)
1.20 (0.76-1.90)
Quartile 4 74/129
Notes: a. Adjusted for body mass index, education level, age of menopause, needle aspiration, energy
expenditure from recreational activity, years since quitting hormone replacement therapy, duration of estrogen
and progesterone use and ethnicity
b. Adjusted for body mass index and education level
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Table 4. Odds ratios (OR) and 95% confidence intervals of breast cancer by sleep duration
Number
Unadjusted OR
Fully Adjusted ORa
Fully Adjusted and
of cases/
(95% CI)
(95% CI)
Creatinine Adjusted
controls
Melatonin Levelsb
OR (95% CI)

1.00 (referent)
1.00 (referent)
1.00 (referent)
5 hours 19/36
or less
0.87 (0.43-1.75)
0.87 (0.43-1.77)
6 hours 68/134 0.94 (0.50-1.79)
1.05 (0.53-2.11)
1.06 (0.53-2.15)
7 hours 107/209 0.96 (0.51-1.80)
0.92 (0.43-1.97)
0.89 (0.41-1.92)
8 hours 49/104 0.88 (0.45-1.73)
14/28
0.92 (0.38-2.21)
0.71 (0.26-1.92)
0.84 (0.51-1.38)
9+
hours
Notes: a. Adjusted for body mass index, education level, age of menopause, needle
aspiration, energy expenditure from recreational activity, years since quitting hormone
replacement therapy, duration of estrogen and progesterone use and ethnicity
b. Adjusted for creatinine adjusted melatonin level, body mass index, education level,
age of menopause, needle aspiration, energy expenditure from recreational activity, years
since quitting hormone replacement therapy, duration of estrogen and progesterone use and
ethnicity
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Table 5. Odds ratios (OR) and 95% confidence interval of breast cancer by
smoking status and ER+ receptor status
Number of
cases/controls

Removed current
smokersa

Number of
cases/controls

ER+a

Quartile 1
50/116
1.0 referent
52/96
1.0 referent
Quartile 2
57/124
1.01 (0.60-1.70)
42/98
0.69 (0.39-1.23)
Quartile 3
70/121
1.19 (0.70-2.02)
52/96
0.72 (0.40-1.29)
Quartile 4
60/116
1.41 (0.81-2.44)
49/99
0.83 (0.46-1.51)
Notes: a. Adjusted for body mass index, education level, age of menopause, needle aspiration, energy
expenditure from recreational activity, years since quitting hormone replacement therapy, duration of
estrogen and progesterone use and ethnicity
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Table 6. Odds ratios (OR) and 95% confidence intervals of breast cancer and creatinine
adjusted melatonin by year of diagnosis
Number of
Less than 4
Number 4-7 yearsa
Number of
7 or more
a
cases/
years
of cases/
cases/
yearsa
controls
controls
controls
15/40
1.00
20/39
1.00
20/39
1.00
Quartile
(Referent)
(Referent)
(Referent)
1
17/40
0.86
17/40
0.52
20/40
0.85
Quartile
(0.32-2.30)
(0.18-1.52)
(0.37-1.94)
2
26/40
1.42
24/39
1.79
20/40
0.81
Quartile
(0.54-3.75)
(0.67-4.76)
(0.33-1.95)
3
22/40
1.40
18/40
1.26
20/40
0.94
Quartile
(0.51-3.81)
(0.49-3.12)
(0.42-2.13)
4
Notes: a. Adjusted for body mass index, age of menopause, needle aspiration, energy expenditure
from recreational activity, years since quitting hormone replacement therapy, duration of estrogen
and progesterone use and ethnicity
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